circulating tumor DNA

Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)

By MedXY 11/13/2025

This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.

Clinical Updates news Oncology Pathology & Lab Medicine Specialties

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma

By MedXY 09/20/2025

Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.

Clinical Updates Hematology-Oncology news Pathology & Lab Medicine Specialties

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma

By MedXY 09/10/2025

Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.

news Oncology Pathology & Lab Medicine Specialties

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer

By MedXY 09/04/2025

Pretreatment circulating tumor DNA levels can predict which patients with advanced ER-positive, HER2-negative breast cancer benefit more from first-line CDK4/6 inhibitor therapy, supporting personalized treatment strategies.